Discussion on Safety Management Defects
Release time:
2020-07-22
Safety Management Defects Discussion
Accidents are caused by unsafe behaviors of people, unsafe conditions of things and management defects. Although the management defects in the three major factors are ranked at the end, in the long run, safety management has a decisive impact on the two major accident causes of unsafe behavior of people and unsafe state of things at the same time. Therefore, the inspection and evaluation of the safety management status is the focus of the company's safety supervision of various enterprises in the next stage. Summarizing the previous safety management situation, the management defects are more or less manifested in the following ten aspects:
1. Safety management organization defects. Mainly in the safety management organization, personnel composition does not adapt to the production system; not according to the requirements of the safety quality of the appropriate, sufficient management personnel, resulting in the safety management of the existence of improper convergence, management gaps, etc.; personnel cross authority, resulting in management confusion.
2. Safety rules and regulations are flawed. It is mainly manifested in the failure to formulate and improve the safety production responsibility system and safety production management system according to its own characteristics, resulting in no rules to follow in the work and chaotic production sequence; the safety production responsibility system is not implemented in every link, every post and every person, and their respective responsibilities are not clear; there is a lack of mutual cooperation and promotion mechanism between different safety rules and management systems; the safety rules and management system is mere formality, with imperfect and incomplete content; the requirements of safety rules and regulations are out of touch with the actual work, etc.
3. Insufficient safety quality of employees. Insufficient safety education and training for employees, safety management personnel and grassroots operators have not received training or insufficient training hours, and do not have the corresponding safety production knowledge and job ability; The quality of employees is low, the knowledge is outdated, and the concept is backward, resulting in poor safety awareness and a large number of unsafe behaviors; The safety education and training of foreign employees are ignored.
4. loose management of hazardous chemicals, hazardous processes and major hazard sources, inadequate monitoring measures, insufficient risk identification, unclear control methods, insufficient prevention and emergency treatment, and backward predictive management methods.
5. The supervision, inspection and assessment of management personnel are insufficient, there are prohibitions, orders, illegal behaviors, and special operation safety management is not in place.
6. Hidden dangers are not thoroughly investigated and control measures are not appropriate.
7. New construction, renovation projects or new equipment of enterprises fail to carry out "three simultaneous" safety facilities as required, resulting in congenital deficiency of safety production conditions.
8. Insufficient investment in safety funds, insufficient safety education and training, inadequate personal protection, insufficient safety facilities, and failure to provide funds for the investigation and management of hidden dangers of accidents have led to accidents.
9. Failure to establish safety production record files is not conducive to timely, comprehensive and systematic grasp of the safety production situation of enterprises and timely reflection of safety production trends; It is not conducive to analyzing the risk factors in safety production and making safety management decisions. The safety management system has not formed a virtuous circle mode of "PDCA .
10. Improper management of accidents (including attempts) has worsened the accidents, such as late reporting, omission, false reporting or concealment of the accidents, failure to find out the cause of the accidents, failure to educate the masses, etc., thus causing minor accidents (signs) to become major accidents. (Safety Management Office of CNPC)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page